Conversion from tacrolimus‐mycophenolate mofetil to tacrolimus‐<scp>mTOR</scp> immunosuppression after kidney‐pancreas transplantation reduces the incidence of both <scp>BK</scp> and <scp>CMV</scp> viremia

Abstract

Conversion from TAC/MMF into TAC/mTOR immunosuppression after KP transplantation reduced the incidences of BK and CMV viremia with an equivalent risk of acute rejection and similar renal/pancreas function.